Pharmaceutical Technology on MSN6d
Arbor to advance gene editing treatments with $73.9m fundingArbor Biotechnologies has closed $73.9m for its gene editing therapeutic pipeline aimed at liver and central nervous system ...
A pair of privately-held developers of editing-based therapies have some successes to show for their recent efforts to ...
US genetic medicines firm Arbor Biotechnologies has announced the closing of a $73.9 million Series C financing to support ...
Alnylam Pharmaceuticals, Inc.’s ALNY share price has surged by 11.75%, which has investors questioning if this is right time ...
Alnylam Pharmaceuticals (NASDAQ:ALNY – Free Report) had its price target increased by Canaccord Genuity Group from $385.00 to $390.00 in a report issued on Friday,Benzinga reports. The brokerage ...
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Alnylam Pharmaceuticals's whale activity within a strike price range from $210.0 to $340 ...
The Canadian Press on MSN4d
Nova Scotia NDP questions lack of pharmacare deal with OttawaHALIFAX — Nova Scotia still hasn’t signed on to the federal government’s pharmacare plan, and the province’s Opposition New ...
Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Free Report) gapped up prior to trading on Friday after Citigroup raised their price target on the stock from $338.00 to $351.00. The stock ...
Clinicians should continue to monitor UACR or UPCR in at-risk children. During periods of rapid growth such as puberty, children with low GFR may show rapid decline in kidney function. Puberty is a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback